Endotoxin-neutralizing peptides as gram-negative sepsis therapeutics

Protein Pept Lett. 2009;16(5):539-42. doi: 10.2174/092986609788167761.

Abstract

Bacterial endotoxin [e.g. lipopolysaccharide (LPS)] can trigger systemic hyper-inflammatory that subsequently leads to multiple organ failure and lethality (gram-negative sepsis). This paper describes the development of endotoxin-neutralizing peptides that potentially treat sepsis. These peptides have been derived from bactericidal/permeability-increasing protein (BPIP), anti-microbial peptides, and leukocyte CD18 antigen and some of these peptides have been tested in clinical studies.

Publication types

  • Review

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antimicrobial Cationic Peptides / chemistry
  • Antimicrobial Cationic Peptides / metabolism
  • Antimicrobial Cationic Peptides / pharmacology
  • Antimicrobial Cationic Peptides / therapeutic use
  • CD18 Antigens / chemistry
  • CD18 Antigens / metabolism
  • CD18 Antigens / pharmacology
  • CD18 Antigens / therapeutic use
  • Endotoxins / antagonists & inhibitors*
  • Endotoxins / metabolism
  • Gram-Negative Bacteria / drug effects
  • Gram-Negative Bacteria / physiology*
  • Humans
  • Molecular Sequence Data
  • Peptides / chemistry
  • Peptides / metabolism
  • Peptides / pharmacology*
  • Peptides / therapeutic use*
  • Sepsis / drug therapy*

Substances

  • Antimicrobial Cationic Peptides
  • CD18 Antigens
  • Endotoxins
  • Peptides